Selection and management of hepatocellular carcinoma patients with sorafenib: Recommendations and opinions from an Italian liver unit

Future Oncology

Volumn 9, Issue 4, 2013, Pages 485-491

  D'Angelo, Salvatore ^a   Secondulfo, Mario ^a   De Cristofano, Raffaele ^a   Sorrentino, Paolo ^a  

^a Hospital SG Moscati   (Italy)

Author keywords

adverse event; hepatocellular carcinoma; patient selection; sorafenib

Indexed keywords

ACETORPHAN; AMYLASE; BILIRUBIN; LANSOPRAZOLE; SORAFENIB; SULPIRIDE; TRIACYLGLYCEROL LIPASE;

ABDOMINAL PAIN; ARTERIAL THROMBOEMBOLISM; ARTICLE; BLEEDING; CANCER SURVIVAL; CARDIOMYOPATHY; CHILD PUGH SCORE; DESCRIPTIVE RESEARCH; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; FATIGUE; HAND FOOT SYNDROME; HEART ATRIUM FIBRILLATION; HUMAN; HYPERBILIRUBINEMIA; HYPERTENSION; INCIDENCE; ITALY; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DYSFUNCTION; LIVER FUNCTION; MULTICENTER STUDY (TOPIC); PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; TREATMENT DURATION;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; FIBROSIS; HEPATITIS B; HEPATITIS C; HUMANS; HYPERTENSION; ITALY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MIDDLE AGED; NIACINAMIDE; PATIENT SELECTION; PHENYLUREA COMPOUNDS; WEIGHT LOSS;

EID: 84875955916     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.208     Document Type: Article

References (34)

1. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig. Liver Dis. 42, S206-S214 (2010).
2. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005). (Pubitemid 40372904)
3. Ikai I, Arii S, Ichida T, et al. Report of the 16th follow-up survey of primary liver cancer. Hepatol. Res. 32(3), 163-172 (2005). (Pubitemid 41070387)
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N. Engl. J. Med. 340(10), 745-750 (1999). (Pubitemid 29114292)
5. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 362, 1907-1917 (2003). (Pubitemid 37518510)
6. Finn RS. Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin. Cancer Res. 16, 390-397 (2010).
7. Llovet JM, Ricci S, Mazzaferro V, et al.; SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378-390 (2008).
8. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a Phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10, 25-34 (2009).
9. Scandurra G, Aiello RA, Alì M, et al. Appropriate management of cutaneous adverse events maximizes compliance with sorafenib treatment: a single-center experience. Future Oncol. 8(5), 609-615 (2012).
10. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur. J. Cancer 47, 2117-2127 (2011).
11. Yau T, Chan P, Ng KK, et al. Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population: presence of lung metastasis predicts poor response. Cancer 115, 428-436 (2009).
12. Pinter M, Sieghart W, Graziadei I, et al. Sorafenib in unresectable hepatocellular carcinoma from mild to advanced stage liver cirrhosis. Oncologist 14, 70-76 (2009).
13. Kim JE, Ryoo BY, Ryu MH, et al. Sorafenib for hepatocellular carcinoma according to Child-Pugh class of liver function. Cancer Chemother. Pharmacol. 68(5), 1285-1290 (2011).
14. Wörns MA, Weinmann A, Pfingst K, et al. Safety and efficacy of sorafenib in patients with advanced hepatocellular carcinoma in consideration of concomitant stage of liver cirrhosis. J. Clin. Gastroenterol. 43(5), 489-495 (2009).
15. Chiu J, Tang YF, Yao TJ, et al. The use of single-agent sorafenib in the treatment of advanced hepatocellular carcinoma patients with underlying Child-Pugh B liver cirrhosis: a retrospective analysis of efficacy, safety, and survival benefits. Cancer 118(21), 5293-52301 (2012).
16. Lencioni R, Kudo M, Ye SL, et al. First interim analysis of the GIDEON (Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib) non-interventional study. Int. J. Clin. Pract. 66(7), 675-683 (2012).
17. Marrero J, Lencioni R, Kudo M, et al. Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of its Treatment with Sorafenib (GIDEON) second interim analysis in more than 1,500 patients: clinical findings in patients with liver dysfunction [abstract]. J. Clin. Oncol. 29(Suppl. 15), 4001 (2011).
18. Peck-Radosavljevic M, Greten TF, Lammer J, et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur. J. Gastroenterol. Hepatol. 22(4), 391-398 (2010).
19. Sacco R, Bargellini I, Ginanni B, et al. Long-term results of sorafenib in advanced-stage hepatocellular carcinoma: what can we learn from routine clinical practice? Expert Rev. Anticancer Ther. 12(7), 869-875 (2012).
20. Iavarone M, Cabibbo G, Piscaglia F, et al.; SOFIA (Sorafenib Italian Assessment) Study Group. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 54(6), 2055-2063 (2011).
21. Maitland ML, Kasza KE, Karrison T, et al. Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment. Clin. Cancer Res. 15, 6250-6257 (2009).
22. Porto I, Leo A, Miele L, Pompili M, Landolfi R, Crea F. A case of variant angina in a patient under chronic treatment with sorafenib. Nat. Rev. Clin. Oncol. 7(8), 476-480 (2010).
23. Frieling T, Heise J, Wassilew SW. Multiple colon ulcerations, perforation and death during treatment of malignant melanoma with sorafenib. Dtsch Med. Wochenschr. 134(28-29) 1464-1466 (2009).
24. Porta C, Paglino C, Imarisio I, Bonomi L. Uncovering Pandora's vase: the growing problem of new toxicities from novel anticancer agents. The case of sorafenib and sunitinib. Clin. Exp. Med. 7, 127-134 (2007).
25. Saadati H, Saif MW. Sorafenib-induced acute pancreatitis. J. Pancreas 11(3), 283-284 (2010).
26. Kumar R, Crouthamel MC, Rominger DH, et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br. J. Cancer 101(10), 1717-1723 (2009).
27. Lee WJ, Lee JL, Chang SE, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br. J. Dermatol. 161(5), 1045-1051 (2009).
28. Bracarda S, Ruggeri EM, Monti M, et al. Early detection, prevention and management of cutaneous adverse events due to sorafenib: recommendations from the Sorafenib Working Group. Crit. Rev. Oncol. Hematol. 82(3), 378-386 (2012).
29. Iavarone M, Perrino M, Viganò M, Beck- Peccoz P, Fugazzola L. Sorafenib-induced destructive thyroiditis. Thyroid 20(9), 1043-1044 (2010).
30. Guy J, Kelley RK, Roberts J, Kerlan R, Yao F, Terrault N. Multidisciplinary management of hepatocellular carcinoma. Clin. Gastroenterol. Hepatol. 10(4), 354-362 (2012).
31. Cabibbo G, Rolle E, De Giorgio M, et al.; HCC Working Group. Management of cirrhotic patients with hepatocellular carcinoma treated with sorafenib. Expert Rev. Anticancer Ther. 11(12), 1807-1816 (2011).
32. US FDA. FDA approval for sorafenib tosylate. www.cancer.gov/cancertopics/ druginfo/fda-sorafenib-tosylate (Accessed 27 November 2012)
33. Bruix J, Sherman M. AASLD Practice Guideline. Management of hepatocellular carcinoma: an update. www.aasld.org/practiceguidelines/ Documents/Bookmarked%20Practice%20 Guidelines/HCCUpdate2010.pdf (Accessed 27 November 2012)
34. National Health Service. Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line). http://guidance.nice.org.uk/TA/Wave17/8 (Accessed 27 November 2012)